

07 May 2026

FOI REQUEST Ref:37036

MS Drug usage

Question One:

How many patients has your trust treated in the past six months (for any disease) with the following drugs:

<i>Drug Name</i>	<i>Patient Numbers</i>
Aubagio (teriflunomide)	0
Avonex (interferon beta-1a)	26
Betaferon (interferon beta-1b)	<5
Brabio (glatiramer acetate)	0
Copaxone (glatiramer acetate)	48
Extavia (beta interferon-1b)	0
Gilenya (fingolimod)	0
Kesimpta (ofatumumab)	46
Lemtrada (alemtuzumab)	0
Mavenclad (cladribine)	<5
Mayzent (siponimod)	14
Ocrevus (ocrelizumab)	225
Plegridy (peginterferon beta-1a)	14
Ponvory (ponesimod)	0
Rebif (beta interferon-1a)	15
Tecfidera (dimethyl fumarate)	0
Tysabri (natalizumab)	39
Tysabri (natalizumab) Pre-filled syringes only	45
Vumerity (diroximel fumarate)	31
Zeposia (ozanimod)	0
Fingolimod generic	48
Tyruko (Natalizumab Biosimilar)	0
Briumvi (ublituximab)	0
Dimethyl fumarate generic	252
Teriflunomide generic	96

07 May 2026

Question Two:

How many patients has your trust treated with Rituximab for MS (Multiple Sclerosis) in the past six months?

0 in Belfast trust

Question Three:

How many patients within your trust have a diagnosis of MS (Multiple Sclerosis)?

2799 – Question 4 details the numbers of patients with a confirmed diagnosis of each type of MS.

Question Four:

Of the patients with a diagnosis of Multiple Sclerosis, how many patients have a diagnosis of:

<i>Condition</i>	<i>Patient Numbers</i>
RRMS – Relapse Remitting Multiple Sclerosis	1825
PPMS – Primary Progressive Multiple Sclerosis	139
SPMS – Secondary Progressive Multiple Sclerosis	417